Stock listing

NASDAQ:CTY City Therapeutics, Inc. Stock

Home listing (NASDAQ) of City Therapeutics, Inc.

Follow City Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CTY

$19.32 USD +2.68 (+16.1%)

Close on Nov 20, 2026

Past month -13.7% · daily closes, Oct 16, 2026 – Nov 20, 2026, adjusted for splits
Day range
$16.96 – $20.62 USDNov 20, 2026
Volume
250,121 sharesNov 20, 2026
Market cap
$972.4M USDAt the close on Nov 20, 2026 · price × 50.33M shares outstanding
Traded on an average day
$6.56M USDMedian day 275,529 shares · last 3 months, Oct 16, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CTY · Home$19.32 USD+2.68 (+16.1%)250,121$18.35$20.62$16.96$16.64Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 16, 2026 – Nov 20, 2026 · NASDAQ:CTY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$19.32+2.68+16.1%$18.35$20.62$16.96250,121
$16.64-0.86-4.9%$17.51$18.76$16.26252,983
$17.50+0.52+3.1%$16.96$17.69$16.43321,270
$16.98-1.12-6.2%$18.11$18.11$16.69238,266
$18.10-0.88-4.6%$18.77$20.33$16.93482,372
$18.98+1.97+11.6%$16.96$19.43$16.65214,891
$17.01-2.61-13.3%$19.65$21.31$16.21458,676
$19.62+0.95+5.1%$19.18$19.76$18.94423,475
$18.67+0.42+2.3%$18.30$18.85$17.88245,189
$18.25+1.18+6.9%$17.95$18.56$17.49311,818
$17.07+0.66+4.0%$16.28$17.32$15.81209,635
$16.41-2.68-14.0%$19.37$20.07$16.22359,719
$19.09-1.79-8.6%$21.12$21.12$18.77275,529
$20.88+0.17+0.8%$21.08$22.65$20.39224,372
$20.71-1.43-6.5%$22.08$22.26$20.37116,775
$22.14+0.49+2.3%$21.63$22.35$21.54130,916
$21.65+0.79+3.8%$20.89$21.96$20.50335,293
$20.86+0.07+0.3%$20.79$21.59$20.70214,807
$20.79+0.02+0.1%$20.62$21.31$20.30136,056
$20.770.000.0%$20.62$21.14$20.03343,835
$20.77+0.34+1.7%$20.41$20.88$19.75127,600
$20.43-0.40-1.9%$20.78$21.69$19.97283,100
$20.83-0.63-2.9%$21.44$21.50$20.00632,800
$21.46-0.94-4.2%$21.94$22.00$21.03302,400
$22.40——$23.00$23.88$20.501,406,100
Ticker
NASDAQ:CTY
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All City Therapeutics, Inc. news

City Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 4 in all · newest Nov 10, 2026 · oldest 2026

Where City Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CTY · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CTYBOATSUnited StatesUSD

Valuation

EV/sales 59.2× against a median of 8.6×: 5th lowest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$802.8M USD
P/E
Loss
EV/sales
59.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Not reported
Operating margin
−441.8%
Net margin
−431.4%
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
City Therapeutics, Inc. · NASDAQ:CTYUS$972.4MUS$802.8Mn/a59.2×n/an/a−431.4%n/an/a
Alto Neuroscience, Inc. · NYSE:ANROUS$1.02BUS$711.7Mn/an/an/a3.4×n/a0.1×1.65
Inhibrx Biosciences, Inc. · NASDAQ:INBXUS$1.02BUS$1.09Bn/a546×n/an/an/an/a1.89
Duality Biotherapeutics, Inc. · HKEX:9606US$992.4MUS$608.3Mn/a4.8×n/a4.6×−170.8%0.3×n/a
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.7MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.5MUS$711.7M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Peptron, Inc. · KRX:087010US$979.5MUS$942.4Mn/a211×n/a10.2×−342.2%0.2×n/a
Seaport Therapeutics, Inc. · NASDAQ:SPTXUS$966.2MUS$675.8Mn/an/an/a2.4×n/a0.0×0.72
MoonLake Immunotherapeutics · NASDAQ:MLTXUS$942.1MUS$543.7Mn/an/an/a2.5×n/a0.3×1.32
Savara, Inc. · NASDAQ:SVRAUS$939.9MUS$840.4Mn/an/an/a8.7×n/a0.3×1.42
Median of the othersUS$981.6MUS$776.1M10.4×8.6×95.7×3.0×−2.2%0.2×1.53

Team and board

Officers

OfficerRole
Andy OrthChief Executive Officer
Keith RegnanteChief Financial Officer
Sebastian TrousilChief Operating Officer
Mary Beth DeLenaChief Legal Officer and Secretary
Ari NowacekSVP, Corporate Development
Anna O’DriscollChief Human Resources Officer
Baisong MeiChief Medical Officer
John MaraganoreExecutive Chair
Tracy ZimmermannChief Scientific Officer

Board

DirectorRole
John MaraganoreExecutive Chair
Barry GreeneBoard Director
Robert NelsenBoard Director
Ron PhilipBoard Director
Sara NochurBoard Director

Financings

RaiseDate
Public offering of common stock
Closed: US$230M raised · US$18 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), Stifel (co-lead), Oppenheimer & Co. (co-lead)
Oct 19, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Oct 15, 2026.

Price
US$18.00 a share
Shares offered
11,111,111 shares of common stock
Offering size
US$200 million
Underwriters' option
Up to 1,666,666 more shares
Listing
CTY on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Stifel, Oppenheimer & Co. · In the order on the cover
Shares delivered
On or about Oct 19, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJul 15, 2026
Filed publiclySep 24, 2026
Amended onceOct 9, 2026
Shares registered with an exchangeOct 13, 2026
Declared effective by the SECOct 15, 2026
Final prospectus, with the priceOct 16, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 16, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012
Revenue13.6M2.78M8.16B8.49B8.55B8.91B8.96B8.84B8.75B8.85B
Cost of revenue2.44B2.77B2.88B2.93B2.87B2.88B2.79B2.87B
Gross profit5.72B5.73B5.67B5.98B6.09B5.96B5.96B5.98B
Research and development58.4M25.7M
Selling, general and administrative15.1M6.19M659.0M799.0M925.0M1.02B1.01B1.09B1.06B1.17B
Operating income-59.9M-29.1M2.88B2.66B2.31B2.32B2.26B2.11B2.08B1.91B
Depreciation and amortization1.17M424.0K1.36B1.44B1.58B1.68B1.84B1.97B2.08B2.23B
EBITDA-58.8M-28.7M4.25B4.10B3.89B4.00B4.10B4.08B4.15B4.13B
Interest expense2.26M448.0K448.0M465.0M478.0M473.0M464.0M450.0M443.0M
Income before tax-58.5M-27.8M2.47B2.16B1.79B1.76B1.73B1.61B1.57B1.39B
Income tax641.0M494.0M134.0M678.0M659.0M639.0M602.0M542.0M
Net income-58.5M-27.8M1.83B1.67B1.66B1.08B1.07B970.0M964.0M849.0M
Earnings per share, basic-1.21-0.58

Balance sheet

LineFY2025FY2024FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012
Cash and equivalents112.8M126.9M2.00M5.00M1.00M5.00M3.00M6.00M14.0M8.00M
Receivables1.21M1.35M514.0M546.0M646.0M700.0M688.0M740.0M738.0M709.0M
Current assets116.9M128.9M2.49B1.85B1.77B1.71B1.60B1.85B1.75B1.57B
Goodwill9.36B9.36B9.36B9.35B9.35B9.35B9.35B9.37B
Total assets149.8M145.4M21.0B20.6B20.9B21.1B21.5B22.5B16.0B16.7B
Accounts payable2.69M2.34M403.0M441.0M317.0M398.0M369.0M464.0M440.0M456.0M
Current liabilities38.0M20.7M3.41B2.27B2.20B2.80B2.42B2.26B2.70B2.83B
Long-term debt31.1M
Total debt5.95B5.96B7.28B7.26B7.24B7.38B7.56B7.63B
Total liabilities234.4M174.8M10.9B10.7B11.5B12.5B12.6B13.3B13.6B14.0B
Shareholders' equity-84.7M-29.4M10.1B9.87B9.34B8.69B8.91B9.18B9.61B9.97B
Shares outstanding48.4M48.4M

Cash flow

LineFY2025FY2024FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012
Cash from operations-41.6M-20.4M3.33B3.79B2.44B2.65B2.59B2.80B2.71B2.77B
Capital spending-2.40M-3.54M-1.05B-1.04B-1.33B-1.26B-1.25B-1.17B-1.26B-1.27B
Free cash flow-44.0M-23.9M2.28B2.75B1.11B1.39B1.34B1.64B1.45B1.51B
Cash from investing-1.72B-1.15B-1.44B-1.33B-1.22B-1.25B-1.38B-1.53B
Cash from financing30.9M149.4M-1.61B-2.63B-1.00B-1.32B-1.37B-1.56B-1.33B-1.24B
Dividends paid-1.60B-1.27B-1.00B-1.30B-1.35B-1.40B-1.32B-1.15B
Share buybacks-2.00M-5.00M-1.00M-5.00M-3.00M-6.00M-14.0M-8.00M
Change in cash-13.1M125.7M-5.00M2.00M-4.00M2.00M-3.00M-8.00M6.00M5.00M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 10, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 6, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeOct 26, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 26, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 22, 2026Big-stake noticeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
All 34 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
8-K · Current reportOct 19, 2026Current reportSEC
S-8 · Registration statement for employee plansOct 16, 2026Offer documentSEC
424B4 · ProspectusOct 16, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 16, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringOct 15, 2026Offer documentSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
CERT · Exchange's certificate of listingOct 15, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 13, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 9, 2026Offer documentSEC
S-1 · Registration statementSep 24, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 21, 2026Offer documentSEC
DRS · Draft registration statementJul 14, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from City Therapeutics, Inc.’s releases · as of Oct 19, 2026

Common shares
50,332,279
Fully diluted
50,332,279

Fully diluted

LineSharesAs of
Common shares50,332,279Oct 19, 2026

Share count over time

CountShares
Oct 19, 202650,332,279

Open Cap table

Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Robert Nelsen
Director, 10% owner
Buy170,000USD 18.00US$3.06MOct 19, 2026
ARCH Venture Partners XII, LLC
10% owner
Buy170,000USD 18.00US$3.06MOct 19, 2026

Big stakes

HolderStakeSharesDate
ARCH Venture Fund XII, L.P.25.60%13.7MOct 19, 2026
FMR LLC14.00%7.03MOct 30, 2026
Invus Public Equities, L.P.8.10%4.3MOct 16, 2026
Viking Global Investors LP7.00%3.73MOct 19, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Nelsen
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past)
Board Director · Since at least Oct 19, 2026
John M. Maraganore
Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2021); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); ProKidney Corp. (Director · Jul 11, 2022 – Jun 29, 2023 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Dec 31, 2022 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past)
Executive Chair · Since at least Oct 19, 2026
Baisong MeiChief Medical Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about City Therapeutics, Inc.